Medtronic (MDT) Depreciation & Amortization (CF) (2014 - 2026)

Medtronic has disclosed Depreciation & Amortization (CF) across 13 years of filings, most recently posting $749.0 million for Q1 2026.

• Depreciation & Amortization (CF) for Q1 2026 came in at $749.0 million, up 9.5% year-over-year; the trailing twelve-month figure through Jan 2026 was $3.1 billion (up 15.21% YoY), and the FY2025 annual result was $2.9 billion, up 8.08% from the prior year.
• Depreciation & Amortization (CF) came in at $749.0 million for Q1 2026 at Medtronic, up from $745.0 million in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $840.0 million in Q2 2025 to a low of $649.0 million in Q1 2024.
• The 5-year median for Depreciation & Amortization (CF) is $675.0 million (2024), against an average of $694.5 million.
• Across the five-year window, Depreciation & Amortization (CF) decreased 4.42% in 2024 and grew 28.44% in 2025, its largest moves.
• Medtronic's Depreciation & Amortization (CF) stood at $671.0 million in 2022, then advanced by 0.15% to $672.0 million in 2023, then increased by 0.45% to $675.0 million in 2024, then advanced by 10.37% to $745.0 million in 2025, then increased by 0.54% to $749.0 million in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $749.0 million (Q1 2026), $745.0 million (Q4 2025), and $748.0 million (Q3 2025), per Business Quant data.